In Lek, a Sandoz company, the International Day of People with Disabilities will be marked with a photo exhibition and workshops

  • In Lek, a Sandoz company, integration of disabled people into work processes is implemented on many levels. They are encouraging diversity and inclusion among associates.
  • This year’s International Day of People with Disabilities will be marked with two events: a photo exhibition The Little Prince, Metamorphosis, Auto/Manual by the author Matej Peljhan at the Lek Gallery and empiric workshops for associates in cooperation with the Slovenian Association of Disabled Students.
2. 12. 2015

On the day before the International Day of People with Disabilities in Lek, a Sandoz company, an exhibition by the photographer Matej Peljhan will be opened in the Lek Gallery. Photographs called The Little Prince are showing different perspectives of the lives of disabled people. The author tells us how handicapped human bodies can also reveal beauty and unique perfection. He creates communication and thus encourages diversity through his photographs. At the opening ceremony not only the photographs will be shown, but also his short animated documentary of the same name The Little Prince, featuring a boy with muscular dystrophy for which he received the Vesna Award for Special Achievements at the 18th Festival of Slovenian Film. The photographs will be on display until 29 January, 2016.

Workshops by the Slovenian Association of Disabled Students

Representatives of the Slovenian Association of Disabled Students and Lek, a Sandoz company, are going to conduct workshops focusing on understanding and accepting diversity on December 3 – the International Day of People with Disabilities. Using various simulations and tools, the Novartis associates in Slovenia will have the opportunity to experience the challenges of blind and partially-sighted persons, deaf and hard of hearing persons as well as people with mobility difficulties. Associates will have the chance to use a white cane and a wheelchair. The goal of this initiative is to foster understanding and inclusion of diversity, which enriches and improves collaboration among employees.

Lek, a Sandoz company, has been cooperating with disabled people for several years

Lek, a Sandoz company, has made the effort to include disabled people into their work process. The company employs almost one hundred disabled people and cooperates with additional ninety through sheltered companies. Disabled people are entering the work process in many fields; packaging, production of wood packaging materials, printed material, scanning, occupational safety and fire control as well as environmental protection and security. Apart from that, one of the companies employing the disabled created last year Christmas presents for children of employees working in Lek, a Sandoz company.

The cooperation with disabled people has also been a part of the Novartis Community Partnership Day since the start eleven years ago. This day is dedicated to voluntary activities bringing together numerous Novartis associates across the world lending a hand as volunteers in their local communities as a part of the Novartis global initiative Community Partnership Day.

Among other activities, Lek’s employees took children with special needs to visit the House of Experiments, prepared an exciting day for children with special needs in the swimming pool at Hotel Lek in Kranjska Gora, helped to paint the rooms at the Institute for the Blind and Visually Impaired Children in Ljubljana, Residential home Šiška of the Education, Work and Care Centre Dolfka Boštjančič, and Janez Levec Centre, as well as organized a sports day and creative workshops for children at the Lendava Bilingual Primary School II.

* * *

Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit

Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32